quantum-chemistry
(4)
Creyon Bio
Creyon Bio is a San Diego biotech reinventing how RNA-targeted medicines are designed. Founded in 2019 by former Ionis Pharmaceuticals scientists, the company pairs machine learning with quantum-level molecular modeling in its NucleIQ platform - an AI-Powered Oligo Engineering Engine - to predict the safety, efficacy, and delivery of oligonucleotide-based medicines before they ever reach a lab bench. The goal: replace slow, expensive trial-and-error with computational design rules that make precision therapeutics engineerable 'on demand,' for both rare and common diseases across neuromuscular, CNS, and immunologic areas.
QC Ware Corp.
QC Ware is a Palo Alto-based enterprise software company that builds quantum and quantum-inspired tools for hard scientific problems. Founded in 2014 by veterans of NASA Ames, it started as a hardware-agnostic quantum cloud platform (Forge) and evolved into Promethium, a GPU-accelerated quantum chemistry SaaS that runs density functional theory calculations on molecules up to thousands of atoms, claiming speeds 10 to 100 times faster than legacy tools. The company also runs Q2B, the largest annual practical quantum computing conference, and counts Goldman Sachs, Airbus, BMW and Covestro among its collaborators and investors.
Deep Principle
Deep Principle is an AI-for-Science company spun out of MIT that builds ReactiveAI, a closed-loop R&D platform fusing generative AI, quantum chemistry, and high-throughput experimentation to discover new materials, catalysts, and chemical processes far faster and cheaper than traditional trial-and-error labs. Founded by MIT PhDs Haojun Jia and Chenru Duan, the company targets materials, energy, and pharmaceutical R&D and has reported quantum-chemistry speedups on the order of 20,000x versus conventional DFT.
Fathom Therapeutics
Fathom Therapeutics (formerly Atommap) is a New York and Boston based biotech building Microcosmos, a drug-design engine that fuses quantum chemistry and AI to simulate how proteins actually move inside living cells. By modeling motion instead of static snapshots - reportedly up to 10,000x faster than conventional simulation - the company hunts for the fleeting binding pockets that make 'undruggable' targets druggable, then designs small molecules, degraders, and molecular glues against them. In April 2026 it raised a $47M oversubscribed Series A led by Sutter Hill Ventures.